Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug669 | COVID-19 swap test PCR Wiki | 0.58 |
| drug726 | Cannabis, Medical Wiki | 0.58 |
| drug3163 | Sofosbuvir Wiki | 0.58 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| D012640 | Seizures NIH | 0.67 |
| D000070627 | Chronic Traumatic Encephalopathy NIH | 0.58 |
| D005879 | Tourette Syndrome NIH | 0.58 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| D004827 | Epilepsy NIH | 0.58 |
| D000690 | Amyotrophic Lateral Sclerosis NIH | 0.41 |
| D000755 | Anemia, Sickle Cell NIH | 0.41 |
| D003072 | Cognition Disorders NIH | 0.41 |
| D016472 | Motor Neuron Disease NIH | 0.41 |
| D001714 | Bipolar Disorder NIH | 0.41 |
| D009422 | Nervous System Diseases NIH | 0.33 |
| D005356 | Fibromyalgia NIH | 0.29 |
| D001927 | Brain Diseases NIH | 0.29 |
| D010300 | Parkinsonian NIH | 0.22 |
| D015212 | Inflammatory Bowel Diseases NIH | 0.22 |
| D000070642 | Brain Injuries, Traumatic NIH | 0.20 |
| D003424 | Crohn Disease NIH | 0.18 |
| D001930 | Brain Injuries, NIH | 0.17 |
| D059350 | Chronic Pain NIH | 0.17 |
| D060825 | Cognitive Dysfunction NIH | 0.17 |
| D012598 | Scoliosi NIH | 0.16 |
| D009103 | Multiple Sclerosis NIH | 0.16 |
| D020521 | Stroke NIH | 0.14 |
| D040921 | Stress Disorders, Traumatic NIH | 0.11 |
| D014947 | Wounds and Injuries NIH | 0.11 |
| D013313 | Stress Disorders, Post-Traumatic NIH | 0.10 |
| D004194 | Disease NIH | 0.09 |
| D013577 | Syndrome NIH | 0.06 |
| D003141 | Communicable Diseases NIH | 0.04 |
| D007239 | Infection NIH | 0.03 |
| D045169 | Severe Acute Respiratory Syndrome NIH | 0.03 |
| D018352 | Coronavirus Infections NIH | 0.02 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| HP:0006802 | Abnormal anterior horn cell morphology HPO | 0.58 |
| HP:0007354 | Amyotrophic lateral sclerosis HPO | 0.58 |
| HP:0100754 | Mania HPO | 0.41 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| HP:0001298 | Encephalopathy HPO | 0.29 |
| HP:0002037 | Inflammation of the large intestine HPO | 0.22 |
| HP:0012532 | Chronic pain HPO | 0.19 |
| HP:0100280 | Crohn's disease HPO | 0.18 |
| HP:0001268 | Mental deterioration HPO | 0.17 |
| HP:0001297 | Stroke HPO | 0.16 |
Navigate: Correlations HPO
There are 3 clinical trials
This will be a multistate, multicenter clinical study to determine the efficacy and safety of medical cannabis for a wide variety of chronic medical conditions.
Description: Covid-19 infection rates in cannabis users will be compared to rates in the general population. Our online questionnaire responses will compare infection rates of cannabis users in this study against the Johns Hopkins University Coronavirus Research Center data (https://coronavirus.jhu.edu).
Measure: Prevention of COVID-19 Time: Five yearsDescription: Severity of persistent symptoms in cannabis users testing positive for active infection and/or antibodies will also be compared to the general population. Patients will answer the widely used FLU-PRO questionnaire, which asks about flu symptoms and severity, to capture diagnoses, symptoms, and medical interventions related to COVID-19. The data from cannabis user patients will be compared with national and international data surveys, such as the Covid Symptom Study (https://covid.joinzoe.com/us-2).
Measure: Treatment of COVID-19 Time: Five yearsDescription: The primary objective is to assess the efficacy and safety of medical cannabis as medicine for treatment of chronic pain and other chronic debilitating diseases. Pain will be measured by Brief Pain Inventory (BPI) numeric scale. Change from baseline in BPI will be assessed at 3-month intervals. For prospective associations between cannabis use and outcomes, use of a lagged mixed-effects models will examine temporal associations between cannabis use and pain severity, opioid sparing, and patient satisfaction. Data will be analyzed from baseline and the annual follow-up waves.
Measure: Treatment of Symptoms Time: Five yearsDescription: Secondary objectives include evaluating increases or decreases in quality of life, and increases or decreases in concomitant opioid use. Satisfaction with treatment will be measured by a Visual Analog Score (VAS). Change From baseline in Satisfaction with treatment measured by (VAS) be assessed at 3-month intervals.
Measure: Cannabis Impact on Quality of Life Time: Five yearsDescription: Tertiary objectives will examine preferences for routes of administration, and preferences for THC / CBD ratios. Categorical factors will be summarized using frequencies and percentages, while continuous measure distributions will be described using means, standard deviations, and quartiles of interest.
Measure: Cannabis Route and Dosing Time: Five yearsDescription: Incidence of Treatment-Related Adverse Events will be measured by Physician Global Assessment (PGA) numeric scale. Number of participants with Treatment-Related Adverse Events will be assessed by CTCAE v4.0.
Measure: Monitoring Adverse Events Time: Five yearsThe purpose is to investigate the COVID-19 prevalence, associated morbidity and long-term cognitive deficits in consecutive patients presenting with acute neurological symptoms
Description: To investigate the prevalence of COVID-19 infections in consecutive patients with acute onset of neurological symptoms (with or without prior neurological disease)
Measure: Prevalence of COVID-19 infection in consecutive patients with neurological symptoms Time: 6 monthsDescription: Three months cognitive function (Montreal Cognitive Assessment) of COVID-19 positive patients compared to COVID-19 negative patients
Measure: Three months cognitive function of COVID-19 positive patients Time: 3 monthsDescription: Characterization of the neurological symptoms in neurological COVID-19 positive patients (exploratory endpoint)
Measure: Clinical presentation of neurological symptoms in COVID-19 positive patients Time: 6 monthsDescription: Prevalence of pre-symptomatic and asymptomatic COVID-19pos in acutely admitted patients with a primary complaint of neurological symptoms.
Measure: Prevalence of pre- and asymptomatic COVID-19 positive patients in acutely admitted neurological patients Time: 6 monthsDescription: Prevalence of anosmia in COVID-19pos patients compared to COVID-19neg patients
Measure: Anosmia in COVID-19 positive patients Time: 6 monthsDescription: Neuro-specific and inflammatory blood- and cerebrospinal fluid markers in COVID-19 positive patients compared to COVID-19 negative matched controls
Measure: Exploratory analysis on neuro-specific and inflammatory blood and cerebrospinal fluid markers of COVID-19 infection Time: 24 monthsDescription: Functional and immunologic plasma assays will be employed to analyze proteins and pathways in coagulation and fibrinolysis
Measure: Exploratory analysis of the coagulation profile of COVID-19 positive patients compared to COVID-19neg patients Time: 24 monthsThe purpose is to investigate the COVID-19 prevalence, associated morbidity and long-term cognitive deficits in consecutive patients presenting with acute neurological symptoms
Description: To investigate the prevalence of COVID-19 infections in consecutive patients with acute onset of neurological symptoms (with or without prior neurological disease)
Measure: Prevalence of COVID-19 infection in consecutive patients with neurological symptoms Time: 6 monthsDescription: Three months cognitive function (Montreal Cognitive Assessment) of COVID-19 positive patients compared to COVID-19 negative patients
Measure: Three months cognitive function of COVID-19 positive patients Time: 3 monthsDescription: Characterization of the neurological symptoms in neurological COVID-19 positive patients (exploratory endpoint)
Measure: Clinical presentation of neurological symptoms in COVID-19 positive patients Time: 6 monthsDescription: Prevalence of pre-symptomatic and asymptomatic COVID-19pos in acutely admitted patients with a primary complaint of neurological symptoms.
Measure: Prevalence of pre- and asymptomatic COVID-19 positive patients in acutely admitted neurological patients Time: 6 monthsDescription: Prevalence of anosmia in COVID-19pos patients compared to COVID-19neg patients
Measure: Anosmia in COVID-19 positive patients Time: 6 monthsDescription: Neuro-specific and inflammatory blood- and cerebrospinal fluid markers in COVID-19 positive patients compared to COVID-19 negative matched controls
Measure: Exploratory analysis on neuro-specific and inflammatory blood and cerebrospinal fluid markers of COVID-19 infection Time: 24 monthsDescription: Functional and immunologic plasma assays will be employed to analyze proteins and pathways in coagulation and fibrinolysis
Measure: Exploratory analysis of the coagulation profile of COVID-19 positive patients compared to COVID-19neg patients Time: 24 monthsAlphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports